Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levodopa/carbidopa extended-release - Amneal Pharmaceuticals

Drug Profile

Levodopa/carbidopa extended-release - Amneal Pharmaceuticals

Alternative Names: Carbidopa/levodopa extended-release capsules - Amneal Pharmaceuticals; GSK-587124; IPX-066; NUMIENT; Patrome; Rytary

Latest Information Update: 28 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Impax Pharmaceuticals
  • Developer Amneal Pharmaceuticals
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 28 Jan 2019 Levodopa/carbidopa extended-release is not yet available for Parkinson's disease in Iceland, Norway, Liechtenstein and other European Union countries
  • 12 Jul 2018 Chemical structure information added
  • 21 Jun 2018 Amneal Pharmaceuticals enters into patent litigation settlement agreement with Actavis related to Actavis's submission of an ANDA to the US FDA seeking approval to market a generic version of Rytary® in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top